Genpharmasec News

Genpharmasec Limited Resubmits Clear Copy of Q2 FY2026 Financial Results

Genpharmasec Limited resubmitted clear copies of its financial results for the quarter and half year ended September 30, 2025, following BSE's request due to unclear figures in the previously submitted PDF. The company's standalone results showed total income of Rs 3,639.16 lakhs for the half year, with profit before tax of Rs 308.65 lakhs for the quarter. The consolidated results included subsidiaries Clinigenome India Private Limited (99.99% stake), Genpharmasec Middle East DMCC (52% stake), and Derren Healthcare Private Limited (70% stake). The financial results were reviewed by the Audit Committee and approved by the Board of Directors on November 6, 2025. The auditor's review found no material misstatements in the financial statements prepared in accordance with Indian Accounting Standards.

Genpharmasec Limited Reports No Deviation in Rights Issue Fund Utilization

Genpharmasec Limited confirmed no deviation or variation in the use of proceeds from its Rights Issue for the quarter ended September 30, 2025. The company utilized funds as originally planned across four key objectives: Rs. 1443.58 lakhs to acquire equity shares from shareholders of Derren Healthcare Private Limited to make it a subsidiary, Rs. 289.00 lakhs out of allocated Rs. 588.00 lakhs to repay term loans, Rs. 1643.86 lakhs out of Rs. 1650.00 lakhs for working capital purposes, and Rs. 25.00 lakhs to meet issue expenses. The statement was reviewed by the Audit Committee and submitted to BSE as per SEBI regulations.

Genpharmasec Limited Reports Quarterly Financial Results for September 2025

Genpharmasec Limited's Board of Directors approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company operates primarily in one business segment and has three subsidiaries: Clinigenome India Private Limited (99.99% stake), Genpharmasec Middle East DMCC (52.00% stake), and Derren Healthcare Private Limited (70.00% stake). The board meeting was held on November 6, 2025, commencing at 5:30 p.m. and concluding at 7:25 p.m. The financial statements were prepared in accordance with Indian Accounting Standards and reviewed by auditors Bilimoria Mehta & Co.